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Abstract The treatment of choice of H. pylori infections is
a 7-day triple-therapy with a proton pump inhibitor (PPI)
plus amoxicillin and either clarithromycin or metronida-
zole, depending on local antibiotic resistance rates. The
data on efficacy of eradication therapy in a group of
rheumatology patients on long-term NSAID therapy are
reported here. This study was part of a nationwide,
multicenter RCT that took place in 2000–2002 in the
Netherlands. Patients who tested positive for H. pylori IgG
antibodies were included and randomly assigned to either
eradication PPI-triple therapy or placebo. After completion,
follow-up at 3 months was done by endoscopy and biopsies
were sent for culture and histology. In the eradication group
13% (20/152, 95% CI 9–20%) and in the placebo group
79% (123/155, 95% CI 72–85%) of the patients were
H. pylori positive by histology or culture. H. pylori was
successfully eradicated in 91% of the patients who were
fully compliant to therapy, compared to 50% of those who
were not (difference of 41%; 95% CI 18–63%). Resistance
percentages found in isolates of the placebo group were:
4% to clarithromycin, 19% to metronidazole, 1% to
amoxicillin and 2% to tetracycline.
Introduction
H. pylori eradication is strongly recommended in all
patients with atrophic gastritis and peptic ulcer disease,
but may also benefit subgroups of patients with dyspepsia,
and patients who start with NSAID therapy [1–6]. H. pylori
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eradication therapy is an important component of guidelines
concerning these patients [7, 8].
Currently, non-invasive management strategies and the
widespread shortage in endoscopic capacity insure that
many patients with H. pylori are managed without upper
gastrointestinal endoscopy. The American College of
Gastroenterology recommends that when an endoscopy is
not performed, a serological test, which is the least
expensive means of evaluating for evidence of H. pylori
infection, should be done [9]. When endoscopy is indicated,
biopsy specimens can be taken for microscopic demonstra-
tion of the organism, culture, histology or urease testing.
Nowadays, in the Netherlands, biopsies are not routinely
sent for culture and susceptibility testing of the infecting
strain because of the high costs.
Apart from patient compliance, resistance of Helico-
bacter pylori to antibiotics can decrease the success of H.
pylori eradication therapy. Regimens of choice for eradica-
tion of H. pylori should be guided by local antibiotic
resistance rates. In the Netherlands, the overall prevalence
of resistance to clarithromycin and metronidazol was lower
than in some surrounding countries possibly due to
restrictive use of antimicrobials [10–12]. The advised
treatment in the Netherlands consists of a proton pump
inhibitor (PPI)-triple therapy for 7 days without prior
susceptibility testing. An increase of resistance rates to
antimicrobial agents is however expected because increas-
ing number of patients treated and increasing consumption
of antibiotics, in particular macrolides, was observed in
recent years [13].
The aim of the present study was firstly, to determine the
efficacy of 7-day PPI-triple therapy for H. pylori in a well-
defined group of patients with a rheumatic disease and
serologic evidence of H. pylori infection who were on long-
term NSAID therapy and secondly, to get insight in the
prevalence of antibiotic resistance of H. pylori in the
studied population.
Methods
This study was part of a placebo-controlled randomized
clinical trial of which the clinical results have been
described elsewhere [14], wherein we described that H.
pylori eradication has no beneficial effect on the incidence
of gastroduodenal ulcers or occurrence of dyspepsia in
patients on long-term NSAID treatment. Between May
2000 and June 2002, patients were recruited from eight
rheumatology outpatient departments in six cities in the
Netherlands. Patients with a rheumatic disease were eligible
for inclusion if they were between 40 and 80 years of age,
were positive for H. pylori on serological testing and were
on long-term NSAID treatment. Forty-eight percent used a
gastroprotective drug (7% H2 receptor antagonists [H2RA],
37% proton pump inhibitors [PPI], 7% misoprostol, 3%
used a combination of these). Exclusion criteria were
previous eradication therapy for H. pylori, known allergy
for the study medication or presence of severe concomitant
disease.
Serologic testing for H. pylori IgG-antibodies was
performed with a commercial enzyme-linked immunosor-
bent assay (Pyloriset® new EIA-G, Orion Diagnostica,
Espoo, Finland) according to the manufacturer’s instruc-
tions. A serum sample was considered positive for IgG
antibodies to H. pylori if the test result was ≥250
International Units (IU). This assay has been assessed,
in a population similar to the population in the presented
trial, and has proven a sensitivity and specificity in the
Netherlands of 98–100% and 79–85%, even in patients
on acid suppressive therapy [15–17]. The study protocol
was approved by research and medical ethics committees
of all participating centers and all patients gave written
informed consent.
After stratification by concurrent use of gastroprotective
agents (proton pump inhibitors, H2 receptor antagonists or
misoprostol, but not prokinetics, or antacids), patients were
randomly assigned to receive either H. pylori eradication
therapy with omeprazole 20 mg, amoxicillin 1000 mg, and
clarithromycin 500 mg (OAC) twice daily for 7 days or
placebo. Patients with an allergy for amoxicillin were
treated with omeprazole 20 mg, metronidazole 500 mg
and clarithromycin 250 mg (OMC) or placebo therapy
twice daily for one week in a distinct stratum. All study
personnel and participants were blinded to treatment
assignment for the duration of the study. The study protocol
was approved by research and medical ethics committees of
all participating centres and all patients gave written
informed consent.
At the 2-week follow-up visit, unused study medica-
tion was returned and remaining tablets were counted in
order to check compliance. Patients were considered to
be noncompliant if ≤6 days (85%) of study medication
were used. Three months after baseline, and additionally
if clinically indicated, patients underwent endoscopy of
the upper gastrointestinal tract. A total of eight biopsies
were taken during each endoscopy. Four samples, two
from the antrum and two from the corpus were used for
histology. All biopsies were stained with haematoxylin-
eosin. The slides were scored independently by an
experienced gastrointestinal pathologist and the investi-
gator (HdL), blinded to treatment assignment and
clinical data, according to the updated Sydney classifi-
cation [18]. In case of discrepant results, the specimen
was discussed until agreement was reached. The remain-
ing four biopsies were sent to a microbiological laboratory
for culture and storage at –70°C. A patient was considered
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H. pylori-negative when histology as well as culture was
negative. All isolated strains were assessed for suscepti-
bility to clarithromycin, metronidazole, tetracycline and
amoxicillin at the central laboratory.
Both biopsy specimens of corpus and antrum were
streaked on Columbia agar (CA) (Becton Dickinson,
Cockeysville, MD, USA) with 10% lysed horse blood
(Bio Trading, Mijdrecht, the Netherlands), referred to as
Columbia agar plates, and on CA with H. pylori selective
supplement (Oxoid, Basingstoke, UK). Plates were incu-
bated for 72 h at 37°C in a micro-aerophilic atmosphere
(5% O2, 10% CO2, 85% N2). Identification was carried out
by Gram’s stain morphology, catalase, oxidase, and urea
hydrolysis measurements.
Inocula were prepared from an H. pylori culture grown
on CA plates. MICs of metronidazole, clarithromycin,
tetracycline and amoxicillin were determined by E-test
(AB Biodisk, Solna, Sweden) on CA plates essentially as
described by Glupczynski et al. [19]. CA plates were
inoculated with a bacterial suspension with a turbidity of a 3
McFarland standard (2×108 CFU/mL ). CLSI (tentative)
breakpoints 2009 for susceptibility (S) and resistance (R)
were applied (metronidazole MIC ≤ 8 mg/l (S) and ≥16
mg/l (R), amoxicillin MIC ≤ 0.5 mg/l (S) and ≥ 2 mg/l (R);
tetracycline MIC ≤ 2 mg/l (S) and ≥ 8 mg/l (R), and
clarithromycin MIC ≤ 0.25 mg/l (S) and ≥ 1 mg/l (R)) [20].
Measurements with a Gaussian distribution were expressed
at baseline as mean and SD, and measures with a non-
Gaussian distribution were expressed as the median and
interquartile range (IQR; expressed as the net result of
75th percentile–25th percentile). An additional analysis
compared outcomes (presence of H. pylori after H. pylori
eradication therapy or placebo) between stratum (patients
on gastroprotective drugs (n=165) and not on gastro-
protective drugs (n=182) by computing the homogeneity
of the common odds ratio. SPSS software (version 17.0.0)
was used to perform these analyses. Differences in the
proportions of patients with susceptible and resistant H.
pylori strains and for compliant and non-compliant patients
were analyzed with 95% confidence interval using the
Confidence Interval Analysis (CIA) software for Windows
(version 2.2.0). The level of significance was set at p<
0.05, two sided.
Results
A total of 347 patients consented to be randomly
assigned to eradication therapy (172 patients) or placebo
(175 patients). Anti-H. pylori IgG antibodies were present
in all patients (median titre 1689 [IQR 700-3732]). The
treatment groups were similar in terms of demographic,
rheumatic disease, NSAID and other drug use. Our
eligibility criteria resulted in a study group with mainly
inflammatory rheumatic diseases (rheumatoid arthritis
61%, spondylarthropathy 8%, psoriatic arthritis 7%,
osteoarthritis 9%, other 15%). The most commonly used
NSAIDs were diclofenac (29%), naproxen (18%), and
ibuprofen (13%), most at full therapeutic doses (median
relative daily dose 1 [IQR 0.5–1]). The mean age was
60 years (SD 10), 61% was female. Twenty-two patients
had a known allergy for amoxicillin and received metronida-
zole instead (10 patients) or placebo (12 patients).
Of these 347 patients, data on culture and histology of
304 patients were available (Table 1). In two cases only
culture data were available and in one case only histology
result was available; all three cases met the criteria for H.
pylori-positivity and were found in the placebo group, but
for clarity purposes were left out of Table 1. A total of 32
patients (with no significant differences between eradica-
tion and placebo groups) refused the 3-month endoscopy,
withdrew informed consent, or could not undergo endos-
copy because of adverse events. Seven patients used
anticoagulant therapy ruling out biopsy sampling according
the protocol, and in one patient no biopsy specimens could
be obtained because of discomfort requiring early comple-
tion of the procedure.
At follow-up after 3 months, 79% (120 /152; 95% CI
72–85%) of the patients in the placebo group were H.
pylori-positive by histology or culture of biopsy specimen.
In the eradication group, this number was 13% (20/152;
95% CI 9–20%) (Table 1).
Patients in the placebo group who were H. pylori negative
at 3 months as assessed by culture and histology had
significantly lower titers of H. pylori anti IgG antibodies at
baseline than those who were H. pylori culture- and or
histology-positive (mean difference −1582, 95% CI −2637
to −527, p=0.004). There were no differences between strata
according to the use of gastroprotective drugs for the
presence of H. pylori by culture and or histology (p=0.454).
Compliance was 89% in patients in the eradication
group and 98% in the placebo group with the assigned
regimen (p<0.001). In the eradication group, H. pylori
could not be demonstrated in 91% of patients with full
Table 1 Results of culture and histology on H. pylori
Culture Eradication group
(n=152)
Placebo group
(n=152)
Histology
Total patients,
n=304
H. pylori
positive
H. pylori
negative
H. pylori
positive
H. pylori
negative
H. pylori
positive
10 (6%) 1 (1%) 89 (57%) 9 (6%)
H. pylori
negative
9 (6%) 132 (87%) 22 (15%) 32 (21%)
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compliance (n=136). In patients who did not take all
7 days of eradication therapy (n=16), H. pylori was found
in 50% (difference of 41%; 95% CI 18–63%). No
differences were found in the placebo group.
Antibiotic resistance rates
A total of 105 clinical isolates of H. pylori were available
for susceptibility testing (one isolate per patient; 95 isolates
from the placebo group, ten from the eradication group)
from the six participating laboratories in the Netherlands.
The rates of resistance are summarized in Table 2.
In the placebo group (n=95), resistance was found in 4%
(4/95) to clarithromycin (MIC ≥1 mg/l), in 1% (1/95) and
2% (2/95) intermediate susceptibility to amoxicillin (MIC
1 mg/l) and tetracycline (MIC 4 mg/l), respectively, and in
19% (18/95) resistance to metronidazole.
Amongst these 95 isolates two were resistant to metroni-
dazole in combination with intermediate susceptible to
tetracycline, and one strain was resistant to metronidazole
and clarithromycin. The placebo group had an MIC90 for
clarithromycin of 0.085 mg/l, for metronidazole >256 mg/l,
for tetracycline 0.341 mg/l and for amoxicillin 0.16 mg/l. One
H. pylori strain was resistant to clarithromycin and metroni-
dazole, and intermediate susceptible to tetracycline and
amoxicillin. No difference was found in H. pylori resistance
rates between men and women (P=0.217) or between
patients who used gastroprotective agents and who those
did not (p=0.25). In the eradication group, two strains were
resistant to clarithromycin and three to metronidazole. No
strains were resistant to tetracycline or amoxicillin.
Conclusion and discussion
We report the results of a study on the efficacy of a test
and treat strategy for H. pylori in rheumatology patients
of the Netherlands who were positive for anti-H. pylori
IgG-antibodies. The main findings in the studied patient
population were: (1) a 7-day PPI-triple eradication therapy
either with clarithromycin or metronidazole was efficacious
with eradication rates of 87% (95% CI 80–91%) without prior
testing for susceptibility of the infecting strain; (2) in 21% of
the patients in the placebo group, the positive H. pylori
serology test could not be confirmed by positive culture or
histology; (3) compliance was an important factor for
successful eradication of H. pylori; and (4) prevalence of
antibiotic resistance in H. pylori was low.
The main reason for not performing endoscopy at
baseline was that this was not feasible in everyday
rheumatology practice; therefore, serology was done to test
for H. pylori. The reliability of serological kits for H. pylori
infection has been widely confirmed [21], contributing to
the reputation of serology as a simple, minimally invasive
and inexpensive diagnostic and screening test. The best
available serology test at the time of the study was the
Pyloriset® an EIA-G from Orion Diagnostica, Espoo,
Finland, with a specificity of 79–91% as assessed in
previous studies in the Netherlands, including patients on
acid suppressive therapy [22–24]. This specificity correlates
well with our finding that in the placebo group, H. pylori
could not be confirmed by culture or histology in 21% of
the IgG positive patients. PPI usage (in this study 37% of
the population) can result in false negative invasive and
non-invasive diagnostic tests, such as culture, histology and
13-C urea breath, and should be stopped two weeks before
testing [25]. This does not apply for serology. 13-C urea
breath tests have better accuracy (>90%), but the serology
test used in this study was less expensive and in all study
centres easily available [26]. On the other hand, we must
not overlook that conditions during transport of biopsies are
critical for successful isolation of H. pylori. Possibly, the
antibacterial effect of NSAIDs, as has been suggested in in
vitro studies, might also partly explain a false positive rate
of serology of 21% [27–29]. However, in a randomized
clinical trial of 122 patients, aspirin in combination with a
standard 7-day course OAC eradication was not signifi-
cantly different compared to the standard therapy [29].
Based on culture and histology findings we conclude that one
fifth of our patients were treated superfluously, with possible
risk of side-effects of the eradication medication. Fortunately,
both regimens were generally well tolerated [14].
Resistance to antibiotics in H. pylori is of particular
concern because it is one of the major determinants in the
failure of eradication regimens. Resistance rates for metro-
nidazole and clarithromycin found in this study were similar
as previously observed in other studies in the Netherlands in
the years 1997–98 [10] and 1997–2002 [11, 12, 30, 31]. To
our knowledge, there are no recent data available on H.
pylori antibiotic primary resistance rates in the Netherlands
[32]. In addition, in this study, compliance played a crucial
Table 2 Antibiotic resistance of H. pylori isolates
Antibiotic Resistance rates
Placebo group, n=95 Eradication group, n=10
Clarithromycin 4% 20%
Metronidazole 19% 30%
Tetracyclinea 2% 0
Amoxicillina 1% 0
All patients in the eradication group who were still H. pylori positive
were assigned OAC (omeprazole 20 mg, amoxicillin 1000 mg, and
clarithromycin 500 mg) and not OMC (omeprazole 20 mg, metroni-
dazole 500 mg and clarithromycin 250 mg)
a Intermediate susceptible
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role in success of eradication ofH. pylori, i.e., treatment failure
was as high as 50% in the non compliant group of patients.
Possibly, the high number of tablets that has to be consumed
during H. pylori eradication therapy is a contributing factor
for non-compliance in this group of elderly patients who were
also on other medications.
In conclusion, serology driven test and treat strategy
eradication of H. pylori with a 7-day PPI-triple therapy is
successful in the majority of patients. Success of eradica-
tion is, also in this group of rheumatology patients, to a
great extent determined by compliance.
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